The importance of re-testing IDH status in IDH "wild-type" low grade gliomas

PATH-36. REPEATING TESTING IN IDH WILD TYPE LGG CASES. THE IMPORTANCE OF NEXT GENERATION SEQUENCING
Link to abstract

"the observation of a particularly favorable outcome in a group of 42 patients with IDH wild type LGG (OS=93.7 months) led us to assess IDH mutation with a more sensitive technique. Next Generation Sequencing (NGS) was used to evaluate IDH status in these tumor samples, and the results of NGS assay were compared with previous findings"

"Twenty-one (50%) of the 42 initial IDH wild type LGGs were found to present IDH mutation when tested with NGS. Four patients had R132H mutation and 17 cases showed other IDH mutations (4 patients with IDH2 mutation, 5 patients with IDH1 R132C mutation, 5 patients with IDH1 R132G mutation and 3 patients with IDH1 R132S mutation)."

"Repeating testing in IDH wild type LGG cases is crucial, as well as the technique used to assess this mutation. NGS is able to find IDH mutations in 50% of patients previously misdiagnosed"